Royalty Pharma (RPRX) CFO sells 11,002 shares in trading plan
Rhea-AI Filing Summary
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through entity TPC RP EPA1 LLC, reported selling a total of 11,002 Class A Ordinary Shares of RPRX on August 13, 2026 in open-market or private transactions under a Rule 10b5-1 plan adopted on February 24, 2026. The sales comprised 9,230 shares at a weighted average price of $58.5864 (with individual trades between $57.99 and $58.98) and 1,772 shares at a weighted average price of $59.1415 (with trades between $58.98 and $59.52). Following these transactions, indirect holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in the reporting person’s IRA, and 1,450 shares held by the spouse, plus 1,500 shares held directly. In addition, the reporting person and related family vehicles hold interests exchangeable into 6,448,180 Class A Ordinary Shares via limited partnership interests in RPI US Partners 2019, LP and 1,788,777 Class A Ordinary Shares via Class E Ordinary Shares of Royalty Pharma Holdings Ltd, which are subject to vesting conditions.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Net Seller: 11,002 shares
Net Sell
6 txns
Insider
Coyne Terrance P.
Role
EVP & CFO
Sold
11,002 shs ($646K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Ordinary Shares F1, F2 | 9,230 | $58.5864 | $541K |
| Sale | Class A Ordinary Shares F1, F3 | 1,772 | $59.1415 | $105K |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Class A Ordinary Shares — 0 shares (Indirect, TPC RP EPA1 LLC);
Class A Ordinary Shares — 24,170 shares (Indirect, By Spouse's IRA);
Class A Ordinary Shares — 23,270 shares (Indirect, By IRA);
Class A Ordinary Shares — 1,450 shares (Indirect, By Spouse);
Class A Ordinary Shares — 1,500 shares (Direct)
Footnotes (3)
- F1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on February 24, 2026.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.99 to $58.98 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.98 to $59.52 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Shares sold (block 1): 9,230 shares
Weighted average price (block 1): $58.5864 per share
Shares sold (block 2): 1,772 shares
+5 more
8 metrics
Shares sold (block 1)
9,230 shares
Class A Ordinary Shares sold indirectly via TPC RP EPA1 LLC on August 13, 2026
Weighted average price (block 1)
$58.5864 per share
First sale block; individual trades between $57.99 and $58.98 per share
Shares sold (block 2)
1,772 shares
Second sale block of Class A Ordinary Shares on August 13, 2026
Weighted average price (block 2)
$59.1415 per share
Second sale block; individual trades between $58.98 and $59.52 per share
Total shares sold
11,002 shares
Aggregate Class A Ordinary Shares sold indirectly via TPC RP EPA1 LLC
Spouse's IRA holding
24,170 shares
Indirect Class A Ordinary Share holding by spouse’s IRA after transactions
Exchangeable LP interests
6,448,180 shares
Class A Ordinary Shares exchangeable from RPI US Partners 2019, LP interests
Exchangeable Class E shares
1,788,777 shares
Class A Ordinary Shares exchangeable from Class E Ordinary Shares of RPH, subject to vesting
Key Terms
Rule 10b5-1 plan, weighted average price, limited partnership interests, Class E Ordinary Shares
4 terms
Rule 10b5-1 plan regulatory
"All reported transactions were effected pursuant to a 10b5-1 plan adopted"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
limited partnership interests financial
"hold limited partnership interests in RPI US Partners 2019, LP exchangeable"
An ownership stake in a limited partnership gives an investor the role of a limited partner who provides capital but does not run day-to-day operations; a separate general partner manages the business. It matters because limited partners share profits, losses, and tax benefits but generally cannot lose more than they invested and have little control or liquidity—think of it like quietly funding a small business while someone else manages it, with potential return and risk tied to the venture’s performance.
FAQ
What did Royalty Pharma (RPRX) executive Terrance P. Coyne report selling in this Form 4?
Terrance P. Coyne reported that entity TPC RP EPA1 LLC sold a total of 11,002 Class A Ordinary Shares of Royalty Pharma on August 13, 2026. These were open-market or private sales reported as indirect ownership transactions.
Was the Royalty Pharma (RPRX) insider sale done under a Rule 10b5-1 plan?
Yes. All reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Terrance P. Coyne on February 24, 2026. This indicates the sales followed a pre-arranged trading schedule rather than discretionary timing.
What additional Royalty Pharma (RPRX) equity interests are held through exchangeable securities?
The reporting person and related family vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,788,777 Class A shares, subject to vesting conditions.
Are the reported Royalty Pharma (RPRX) sales direct or indirect holdings of the insider?
The 11,002 Class A shares sold were reported as indirectly held through TPC RP EPA1 LLC. Additional holdings are also largely indirect, via IRAs and the spouse, with only 1,500 Class A shares reported as directly held by the insider.
AI-generated analysis. How Rhea-AI works. Not financial advice.
